• News
  • SAN DIEGO
  • BioTech

Halozyme gains on $4 million payment by Roche

Halozyme Therapeutics Inc. gained after a filing by partner Roche Holding AG with European regulators triggered a $4 million milestone payment.

Halozyme (Nasdaq: HALO) gained 3.5 percent to $5.94 at the close of New York trading. The San Diego-based company has declined 39 percent in the past 12 months.

Halozyme said two days ago that Roche had submitted a line extension application with the European Medicines Agency for a subcutaneous formulation of MabThera for non-Hodgkin lymphoma. That formulation of the medicine, which would shorten treatment times, uses Halozyme technology that Roche licensed in 2006 for as much as $612 million. Halozyme’s technology enables the injection of large amounts of medication under the skin so patients can receive an injection rather than an IV infusion.

“Offering a subcutaneous formulation of MabThera could provide patients with a therapy which is less invasive, shortens administration times and potentially reduces health-care costs,” Gregory I. Frost, Halozyme’s CEO, said in a statement two days ago.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!